Technologies invented and patented by researchers at the Frederick National Laboratory for Cancer Research cross the breath of the FNL’s research in cancer and HIV/AIDS.
Most of these patents are owned by the government and the technologies are available for licensing from the National Cancer Institute's Technology Transfer Center.
Contact Claudia Haywood, J.D., with questions at claudia.haywood@nih.gov.
|
Patent No. |
Title |
FNL Inventors |
|---|---|---|
|
Auto-recognizing therapeutic RNA/DNA chimeric nanoparticles (NP) |
Eckart Bindewald, Ph.D. |
|
|
Compositions related to controllable intervening protein sequences (CIPS) comprising reversible zinc-binding motifs and inteins |
Jianwei Zhu, Ph.D. |
|
|
Nitric oxide-releasing diazeniumdiolated polyvinylpyrrolidone-based polymers, and compositions, medical devices, and uses thereof |
Joseph Hrabie, Ph.D. |
|
|
Antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 and their use |
Thomas Pfister, Ph.D. |
|
|
Processes for production and purification of nucleic acid-containing compositions |
Jianwei Zhu, Ph.D. |
|
|
Triggering RNA interference with RNA-DNA and DNA-RNA nanoparticles |
Mathias Viard, Ph.D. |
|
|
Anti-CD133 monoclonal antibodies and related compositions and methods |
Thomas Pfister, Ph.D. |
|
|
Method for purifying antibodies using PBS |
Samir Shaban, MS |
|
|
Methods of analyzing virus-derived therapeutics |
Trevor Broadt, MS |
|
|
Substitutions-modified prefusion RSV F proteins and their use |
Yaroslav Tsybovsky, Ph.D. |
|
|
Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens |
Yaroslav Tsybovsky, Ph.D. |
|
|
K-Ras modulators |
Anna Maciag, Ph.D. |
|
|
Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment |
Alan Brooks, MS |
|
|
Nanoparticle to target cancer |
Abdullah Mahmud, Ph.D. |
|
|
K-Ras modulators |
Anna Maciag, Ph.D. |
|
|
Anti-pY1235-MET immunological binding reagent |
Apurva Srivastava, Ph.D. |
|
|
Functionally-interdependent shape switching nucleic acid nanoparticles |
Eckart Bindewald, Ph.D. |
|
|
Micro-dose calibrator |
Stephen Adler, Ph.D. |
|
|
Phenyl indole allosteric inhibitors of p97 ATPase |
William Moore, Ph.D. |
|
|
Small molecule inhibitors of lactate dehydrogenase and methods of use thereof |
William Moore, Ph.D. |
|
|
Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers |
Denise Whitby, Ph.D. |
|
|
Photoactivatable lipid-based nanoparticles as vehicles for dual agent delivery |
Mathias Viard, Ph.D. |
|
|
Compounds that bind to human immunodeficiency virus rev response element |
Ping Yu, M.S. |
|
|
Anti-CD133 monoclonal antibodies and related compositions and methods |
Thomas Pfister, Ph.D., |
|
|
Zirconium-89 oxine complex as a cell labeling agent for positron emission tomography |
Gary Griffiths, Ph.D. |
|
|
Prefusion PIV F immunogens and their use |
Yaroslav Tsybovsky, Ph.D. |
|
|
Methods and kits for measuring and quantifying DNA double-stranded breaks using gamma-H2AX and H2AX |
Yiping Zhang, Ph.D., |
|
|
HER2-specific monoclonal antibodies and conjugates thereof |
Boopathy Ramakrishnan, Ph.D. |
|
|
Method for subtyping lymphoma types by means of expression profiling |
Paul Williams, Ph.D., |
|
|
Multifunctional RNA nanoparticles and methods of use |
Mathias Viard, Ph.D. |
|
|
Hyperpolarized media transport vessel |
Marcelino Bernardo |
|
|
1 H-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof |
William Moore, Ph.D. |
|
|
Fixatives and methods of use |
Candice Perry |
|
|
Cellular and viral inactivation |
Julian Bess, Jr., M.S., |